310 related articles for article (PubMed ID: 11555604)
1. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.
Mårlind J; Kaspar M; Trachsel E; Sommavilla R; Hindle S; Bacci C; Giovannoni L; Neri D
Clin Cancer Res; 2008 Oct; 14(20):6515-24. PubMed ID: 18927291
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
[TBL] [Abstract][Full Text] [Related]
4. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
[TBL] [Abstract][Full Text] [Related]
5. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
[TBL] [Abstract][Full Text] [Related]
6. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.
Johnson EE; Yamane BH; Buhtoiarov IN; Lum HD; Rakhmilevich AL; Mahvi DM; Gillies SD; Sondel PM
Clin Cancer Res; 2009 Aug; 15(15):4875-84. PubMed ID: 19638464
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
Feleszko W; Mlynarczuk I; Balkowiec-Iskra EZ; Czajka A; Switaj T; Stoklosa T; Giermasz A; Jakóbisiak M
Clin Cancer Res; 2000 May; 6(5):2044-52. PubMed ID: 10815931
[TBL] [Abstract][Full Text] [Related]
8. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
Rose WC
J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529
[TBL] [Abstract][Full Text] [Related]
9. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.
Connor JP; Cristea MC; Lewis NL; Lewis LD; Komarnitsky PB; Mattiacci MR; Felder M; Stewart S; Harter J; Henslee-Downey J; Kramer D; Neugebauer R; Stupp R
BMC Cancer; 2013 Jan; 13():20. PubMed ID: 23320927
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
11. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
12. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
Song S; Wientjes MG; Walsh C; Au JL
Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
[TBL] [Abstract][Full Text] [Related]
13. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
14. The antitumor effect of postoperative treatment with genistein alone or combined with cyclophosphamide in mice bearing transplantable tumors.
Wietrzyk J; Opolski A; Madej J; Radzikowski C
Acta Pol Pharm; 2000 Nov; 57 Suppl():5-8. PubMed ID: 11293263
[TBL] [Abstract][Full Text] [Related]
15. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
16. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.
Trail PA; Willner D; Bianchi AB; Henderson AJ; TrailSmith MD; Girit E; Lasch S; Hellström I; Hellström KE
Clin Cancer Res; 1999 Nov; 5(11):3632-8. PubMed ID: 10589780
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.
Moschetta M; Pretto F; Berndt A; Galler K; Richter P; Bassi A; Oliva P; Micotti E; Valbusa G; Schwager K; Kaspar M; Trachsel E; Kosmehl H; Bani MR; Neri D; Giavazzi R
Cancer Res; 2012 Apr; 72(7):1814-24. PubMed ID: 22392081
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li C; Price JE; Milas L; Hunter NR; Ke S; Yu DF; Charnsangavej C; Wallace S
Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
